文献速递造血干细胞移植与细胞治疗白血病

联合CD34+干细胞选择与预防性病原体和白血病导向T细胞免疫治疗以同时减少异基因干细胞移植后移植物抗宿主病、感染和白血病复发

Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant.
PubMed 文献 · Am J Hematol · 2022-05-20

该试验设计旨在同时解决异基因干细胞移植后移植物抗宿主病、感染和恶性肿瘤复发问题。采用CD34+干细胞分离减少急慢性移植物抗宿主病,移植后21-28天输注供者来源的巨细胞病毒、EB病毒和烟曲霉特异性T细胞及CD19导向的嵌合抗原受体T细胞。两例急性淋巴细胞白血病患者接受HLA相合同胞移植,未用抗淋巴细胞球蛋白,移植后未用免疫抑制,CAR-T前未行淋巴细胞清除。中性粒细胞和血小板植入迅速,抗原经验T细胞快速出现,四聚体阳性T细胞持续至少1年,CAR-T扩增持续至3个月,两例患者移植后3年余均存活,无移植物抗宿主病或疾病复发证据。

要点

  • CD34+干细胞选择联合预防性病原体和白血病导向T细胞免疫治疗可同时减少移植物抗宿主病、感染和白血病复发。
  • 两例急性淋巴细胞白血病患者移植后未用免疫抑制,中性粒细胞和血小板植入迅速。
  • 抗原经验CD8+和CD4+T细胞快速出现,靶向CMV和EBV的四聚体阳性T细胞持续至少1年。

核心结论

  • 联合强效供者T细胞去除与靶向感染和恶性抗原的定向T细胞过继免疫治疗可独立调节移植物抗宿主病、感染和疾病复发。
  • 该联合方案可能将移植物抗宿主病与移植物抗肿瘤效应分离,加速免疫重建,改善移植耐受性。

研究设计与样本

  • 试验设计旨在同时解决异基因干细胞移植后移植物抗宿主病、感染和恶性肿瘤复发问题。
  • 采用CD34+干细胞分离以减少急性和慢性移植物抗宿主病。
  • 两例急性淋巴细胞白血病患者接受HLA相合同胞移植,使用标准剂量环磷酰胺和全身照射,未用抗淋巴细胞球蛋白。
  • 移植后21-28天给予两次预防性输注:一次为供者来源的巨细胞病毒、EB病毒和烟曲霉特异性T细胞,另一次为供者来源的CD19导向嵌合抗原受体T细胞。
  • 患者移植后未接受免疫抑制,CAR-T细胞输注前未行淋巴细胞清除。

主要发现

  • 中性粒细胞和血小板植入迅速。
  • 过继T细胞输注后,抗原经验CD8+和较少CD4+T细胞快速出现。
  • 靶向CMV和EBV的四聚体阳性T细胞在T细胞输注后快速出现并持续至少1年。
  • CAR-T细胞扩增并持续至3个月。
  • T细胞受体追踪证实血液中存在靶向全部三种病原体的产品来源T细胞克隆。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We designed a trial to simultaneously address the problems of graft versus host disease (GVHD), infection, and recurrence of malignancy after allogeneic stem cell transplantation. CD34+ stem cell isolation was used to minimize the development of acute and chronic GVHD. Two prophylactic infusions, one combining donor-derived cytomegalovirus, Epstein-Barr virus, and Aspergillus fumigatus specific T-cells and the other comprising donor-derived CD19 directed chimeric antigen receptor (CAR) bearing T-cells, were given 21-28 days after transplant. Two patients were transplanted for acute lymphoblastic leukemia from HLA identical siblings using standard doses of cyclophosphamide and total body irradiation without antilymphocyte globulin. Patients received no post-transplant immune suppression and were given no pre-CAR T-cell lymphodepletion. Neutrophil and platelet engraftment was prompt. Following adoptive T-cell infusions, there was rapid appearance of antigen-experienced CD8+ and to a lesser extent CD4+ T-cells. Tetramer-positive T-cells targeting CMV and EBV appeared rapidly after T-cell infusion and persisted for at least 1 year. CAR T-cell expansion occurred and persisted for up to 3 months. T-cell receptor tracking confirmed the presence of product-derived T-cell clones in blood targeting all three pathogens. Both patients are alive over 3 years post-transplant without evidence of GVHD or disease recurrence. Combining robust donor T-cell depletion with directed T-cell adoptive immunotherapy targeting infectious and malignant antigens permits independent modulation of GVHD, infection, and disease recurrence. The combination may separate GVHD from the graft versus tumor effect, accelerate immune reconstitution, and improve transplant tolerability.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Gottlieb DJ, Sutrave G, Jiang W, et al. Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant. Am J Hematol. 2022. PMID: 35560045. doi:10.1002/ajh.26594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。